Navigation Links
PharmAthene Reports Year-End 2007 Financial Results
Date:3/31/2008

t expenses were $16.6 million for the year ended December 31, 2007 and $7.3 million for the same period in 2006. Research and development expense increased $9.3 million in 2007 compared to 2006 primarily as a result of increased process development and manufacturing activities related to Protexia(R) and Valortim(TM) of $9.2 million, and employee-related expenses, including stock compensation expense of $1.8 million. These increases were partially offset by reduced preclinical and clinical activities related mostly to the Valortim(TM) clinical trial program.

General and administrative expenses for the Company in 2007 were $13.9 million compared to $8.5 million for the same period in 2006. The increase in general and administrative costs in 2007 was attributable to increased employee costs, a related increase in travel expense, increased stock compensation expense, and increased facilities costs as PharmAthene relocated its corporate headquarters in 2007 to larger facilities in Annapolis.

PharmAthene's net loss attributable to common shareholders for the year ended December 31, 2007 was $17.7 million or $1.88 per basic and diluted share. Non-cash adjustments for the year ended December 31, 2007 included a $2.4 million credit that resulted from the cancellation of former PharmAthene preferred stock warrants, a $0.9 million gain on the extinguishment of debt, and stock compensation expense of $1.7 million.

As of December 31, 2007, cash, cash equivalents and short term investments were $52.7 million, compared to $5.1 million at December 31, 2006. The $47.6 million increase in cash, cash equivalents and short term investments from December 31, 2006 is primarily attributable to the August 2007 merger with HAQ, which resulted in net cash proceeds of $57.9 million and to the March 2007 $10.0 million credit facility, partially offset by the funding of operations for fiscal year 2007.

On March 20, 2008, PharmAthene announced that the Company had sig
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Rockville, MD (PRWEB) January 23, 2015 ... delivers modern digital workplaces on Microsoft Office 365 and ... 2015 Future 50 Award program for being one of the ... of revenue and employee growth. , “To be recognized ...
(Date:1/22/2015)... GEA Niro Soavi the leader in high pressure ... 2000, which is ideal for new applications for processing ... . This compact laboratory homogenizer is the perfect solution ... additives and ingredients as well as for the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Protocol Networks ... The growing team of brand-neutral, independent consultants, Protocol Networks ... Rogers explained that over the years, his company has ... Moroso, Town of Plainfield, as well as others. With ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently ... Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... education conference for health care professionals. This year’s pre-conference seminar ... probiotics in health. Dr. Leyer spoke about the emerging topics ...
Breaking Biology Technology:Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 2Washington SmartCEO Announces Portal Solutions as 2015 Future 50 Award Winner Second Year in a Row 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2
... CAMBRIDGE, Mass., May 21 Biopure Corporation,(Nasdaq: BPUR ... fiscal,quarter ended April 30, 2008. For the quarter, the ... per common share, compared with a net loss,of $6.2 ... period in,2007. Class A common shares outstanding on April ...
... Genetics,Inc. (Amex: ILI ), today expressed praise ... Nondiscrimination Act (GINA). The bill was approved,unanimously in ... into law by,President George W. Bush today., ... are protected,from genetic discrimination from employers and insurance ...
... The New Best Practice Statements Were Presented at ... YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May ... cryotherapy, announced today that the,American Urological Association has ... cryotherapy. The guidelines state,that cryoablation is a treatment ...
Cached Biology Technology:Biopure Announces 2008 Second Quarter Financial Results 2Biopure Announces 2008 Second Quarter Financial Results 3Biopure Announces 2008 Second Quarter Financial Results 4Biopure Announces 2008 Second Quarter Financial Results 5Biopure Announces 2008 Second Quarter Financial Results 6Biopure Announces 2008 Second Quarter Financial Results 7Biopure Announces 2008 Second Quarter Financial Results 8Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 2Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA) 3American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 2American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 3
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... 2015-2019"  report to their offering. One ... technology. With continuous advances in technology, it is important ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... brains are under intensive development all over the ... areas, according to a study just placed online. ... of Southern California chaired the eight-member committee which ... in Brain-Computer Interfaces," published in October by the ...
... Conn. A before-and-after study led by Yale biologists, ... genetic diversity of marine iguanas on the Galpagos Islands, ... the need to determine which environmental and biological factors ... to the authors, recurring El Nio events provide an ...
... Ossur, an emerging leader in the non-invasive orthopaedics ... is pleased to announce that the Journal of Trauma ... cervical collar study performed by the Mayo Clinic. The ... from Four Cervical Collars, finds that Ossurs products ...
Cached Biology News:Brain-computer link systems on the brink of breakthrough, study finds 2Global climate change: The impact of El Nio on Galpagos marine iguanas 2Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2
... Clone/PAD: ZMD.414. Immunogen: Synthetic peptide ... mouse and rat mTOR (Mammalian target of ... for the human mTOR protein. On ... at ~235 kDa. Reactivity: Human (positive ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Request Info...
Biology Products: